Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Sweden
In shortElos Medtech AB is profitable, generates cash and carries moderate debt, with revenue growing (+22.8% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 13.8% | 63/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 8.4% | 54/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 10.5% | 52/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 7.7% | 52/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.54× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.50× | 83/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.23× | 79/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 3.48× | 19/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.89 | 97/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 12.2% | 69/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.44× | 100/100 |
| Years with positive free cash flow (last 5) | 3 of 3 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 3 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 2 | 100/100 |
| Revenue growth volatility | 1.4% | 100/100 |
| Operating margin volatility | 1.7% | 94/100 |
Weight in the score: 20%
Fiscal year 2022 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 3 fiscal years from the company's annual reports.
SEK millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 | FY22 |
|---|---|---|---|
| Revenue | 580 | 724 | 889 |
| Cost of revenue | 392 | 468 | 578 |
| Gross profit | 188 | 255 | 310 |
| Research & development | 16 | 18 | 24 |
| Operating income | 64 | 101 | 122 |
| Interest expense | 21 | 11 | 35 |
| Pre-tax income | 43 | 98 | 99 |
| Income tax | 7.2 | 22 | 24 |
| Net income | 36 | 76 | 75 |
| Diluted EPS | kr4.47 | kr9.37 | – |
4.89 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2022 · Data updated Dec 31, 2022